Program Description & Educational Objectives

In this activity, experts in pancreatic malignancies discuss standards and advances in treating pancreatic adenocarcinoma and neuroendocrine tumors, as well as practical strategies for managing pain, biliary or gastric obstruction, and venous thromboembolism.

Upon completion of this activity, participants will be able to:

• Assess the latest efficacy and safety data related to the use of established and emerging chemotherapeutic agents and various combinations in pancreatic cancers, and apply the relevant data to treatment plans of patients with these malignancies
• Evaluate the current evidence on the benefits and limitations of targeted therapies in patients with pancreatic malignancies, and develop strategies for optimal integration of these agents into existing treatment protocols
• Develop plans for effective management of disease- or treatment-related complications common in patients with pancreatic malignancies

Target Audience

This activity has been designed to meet the educational needs of oncologists, nurses, pharmacists, and other clinicians involved in managing pancreatic malignancies.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE/CPE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: June 24, 2010 - June 23, 2011
Time to Complete: 30 minutes

Faculty & Disclosure

Course Director and Moderator

Eileen M. O'Reilly, MD
Associate Attending, GI Medical Oncology
Memorial Sloan-Kettering Cancer Center
Associate Professor of Medicine
Weill Medical College of Cornell University
New York, New York

Eileen M. O'Reilly, MD, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca, Ltd. (KuDOS); Bayer HealthCare Pharmaceuticals; Chugai Pharma USA, LLC; ImClone Systems Incorporated; and sanofi-aventis.

Advisory Board for Bayer HealthCare Pharmaceuticals; Celsion Corporation; Chugai Pharma USA, LLC; Clovis Oncology, Inc.; Genentech, Inc.; ImClone Systems Incorporated; Jennerex Biotherapeutics, Inc.; MediGene; Merck & Co., Inc.; Novartis Oncology; OSI Pharmaceuticals, Inc.; Polaris Group; Proacta Inc.; Roche Laboratories Inc.; and sanofi-aventis.

Interviewee

David P. Ryan, MD
Clinical Director
Massachusetts General Hospital Cancer Center
Associate Professor
Harvard Medical School
Boston, Massachusetts

David P. Ryan, MD, has a financial interest/relationship or affiliation in the form of:

Advisory Board for AVEO Pharmaceuticals, Inc.

Content Director

Kadrin Wilfong, MD
PVI, PeerView Institute for Medical Education, Inc.

Kadrin Wilfong, MD, currently has no financial interests/relationships or affiliations in relation to this activity.

All additional planning committee members, PVI, PeerView Institute for Medical Education, Inc. staff, and Purdue University School of Pharmacy staff have no relationships to disclose.

Sponsorship, Credit & Support

Physicians

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Purdue University School of Pharmacy and PVI, PeerView Institute for Medical Education. Purdue University School of Pharmacy, an equal access/equal opportunity institution, is accredited by the ACCME to provide continuing medical education for physicians.

Purdue University School of Pharmacy designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses

Purdue University Continuing Nursing Education is approved as a provider of continuing nursing education by the Indiana State Nurses Association. ISNA is accredited as an approver of continuing education in nursing by the Commission on Accreditation of the American Nurses Credentialing Center. Code #CNEP-09-50.

This program has been approved for 0.5 contact hour(s).

Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.

Pharmacists

Purdue University School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This is a knowledge-based, continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Program Number (UPN): 0018-9999-10-127-H01-P, 0.5 contact hours (0.05 CEUs).

This activity is supported by educational grants from